Previous 10 | Next 10 |
− Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022 – − Company Announces Updated Statistical Analysis Plan and Timing for HELIOS-B Phase 3 Study of ...
Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...
2024-02-14 10:52:49 ET More on Alnylam Pharmaceuticals Alnylam's Huge Opportunity Alnylam Pharmaceuticals: R&D Day Reveals Ambitious Plans Investors growing more bullish on SMID cap biotech stocks Regeneron eyes Wegovy combo to improve quality of weight l...
2024-02-05 14:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today, we're highlighting January 2024 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2023 on Thursday, February 15, 2024, before the U.S. financial markets open. Management will provide...
2024-01-28 11:52:19 ET Summary Baillie Gifford's 13F portfolio value increased from ~$110B to ~$126B this quarter. The top three holdings are MercadoLibre, NVIDIA, and Amazon.com, accounting for ~17% of the portfolio. Baillie Gifford increased stakes in PDD Holdings, Shopify, ...
2024-01-27 15:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-12 10:35:06 ET Summary Pfizer's drug tafamidis has shown positive results in treating transthyretin amyloidosis cardiomyopathy (ATTR-CM), but there is still room for improvement. Alnylam's gene silencer treatments, ONPATTRO and vutrisiran, have shown promise in reducing le...
2024-01-10 12:09:02 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) Am...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, said today that Chief Executive Officer Yvonne Greenstreet has been selected as the 2024 Woman of the Year by the Healthcare Businesswomen’s Association (HBA). The announcement was made last evening at t...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
– Highlighted New Disclosures of Company’s Impact on the Environment—Including Multiyear Data on Greenhouse Gas (GHG) Emissions, Energy, Water, and Waste Management Footprint– – Expanded Alnylam Challengers Global Health Equity Initiative – ...
− Achieved First Quarter 2024 Global Net Product Revenues of $365 Million, Representing 32% Year-Over-Year Growth Compared to Q1 2023, Including Continued Momentum from Total TTR Delivering 29% Year-Over-Year Growth – − Demonstrated Strong Progress with Zilebesiran Hy...